BioSight
Companies
Aurinia Pharmaceuticals Inc. logo

AUPH

NASDAQEDMONTON, A0
Aurinia Pharmaceuticals Inc.

Aurinia Pharmaceuticals develops and commercializes therapies for autoimmune and inflammatory diseases, with a marketed product called LUPKYNIS (voclosporin) for lupus nephritis and a pipeline candidate called aritinercept in development. The company operates under a collaboration and commercial supply agreement with Otsuka Pharmaceutical for LUPKYNIS, and generates revenue from net product sales while working to expand market adoption of this therapy.

Price history not yet available for AUPH.

Pipeline

No pipeline data on record yet.

Catalyst Calendar

No catalyst events on record for yet. Check back after the next daily ingest.

Disclaimer·BioSight aggregates publicly available data (SEC EDGAR, ClinicalTrials.gov, FDA, company press releases) and is provided as is for informational purposes only. Nothing here is investment, financial, legal, tax, or medical advice, or an offer to buy or sell any security. We make no warranty as to accuracy, completeness, or timeliness; dates and filings may contain errors or be superseded without notice; past events do not predict future outcomes. To the maximum extent permitted by law, BioSight, its operators, contributors, and affiliates disclaim all liability for any loss or damage arising from use of or reliance on this site. You are solely responsible for your own investment decisions — consult a licensed professional before acting on any information.

Unlock 12-month calendar